Prevalence of hyperuricemia among type 2 diabetes mellitus patients in Africa: a systematic review and meta-analysis

Abstract

Background Hyperuricemia increases morbidity and mortality in type 2 diabetic individuals. It is linked to the expansion of diabetes and cardiovascular diseases indicators, as well as being a significant predictor of coronary artery disease. It also leads to a poor prognosis and increment of diabetic complications including diabetic neuropathy, retinopathy, and nephropathy. Therefore, this systematic review and meta-analysis was aimed to determine the pooled prevalence of hyperuricemia among type 2 diabetes mellitus patients in Africa. Methods We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. To identify relevant articles, we searched electronic databases such as PubMed, Google Scholar, African Journal Online, Science Direct, Embase, ResearchGate, Scopus, and Web of Sciences. The quality of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale. Statistical analysis was performed using Stata 14.0 software. To evaluate heterogeneity, we utilized Cochran’s Q test and I2 statistics. Publication bias was assessed through the examination of a funnel plot and Egger’s test. The pooled prevalence was estimated using a random effect model. Furthermore, sub-group and sensitivity analyses were conducted. Results The overall pooled prevalence of hyperuricemia among type 2 diabetic patients in Africa was 27.28% (95% CI: 23.07, 31.49). The prevalence was highest in Central Africa 33.72% (95% CI: 23.49, 43.95), and lowest in North Africa 24.72% (95% CI: 14.38, 35.07). Regarding sex, the pooled prevalence of hyperuricemia among female and male type 2 diabetic patients was 28.02% (95% CI: 22.92, 33.48) and 28.20% (95% CI: 22.92, 33.48), respectively. Conclusion This systematic review and meta-analysis showed a high prevalence of hyperuricemia among type 2 diabetic patients. So, regular screening and diagnosis of hyperuricemia required for preventing its pathological effects and contribution to chronic complications of diabetes. Systematic review registration : PROSPERO (2022: CRD42022331279).

Expanding Indications for the Sodium-Cotransporter Glucose 2 Inhibitors Application in Type 2 Diabetes Mellitus

“…Подагра и гиперурикемия связаны с повышением риска инсулинорезистентности и СД2, а с другой стороны, являются потенциальным триггером, вызывающим акселерацию ССЗ и неблагоприятные исходы, включая прогрессию ХБП [41]. Распространенность гиперурикемии при СД2 достигает 30%, что определяет актуальность использования терапевтических подходов, обеспечивающих пользу для этой категории пациентов [42]. ИНКТГ2 усиливают урикозурию, и, хотя точный механизм их действия в снижении уровня мочевой кислоты до конца не изучен, доказано, что использование препаратов этого класса обеспечивает снижение уровня мочевой кислоты на 0,60-0,75 мг/дл у людей с нормальным уровнем мочевой кислоты (3,3-6,7 мг/дл).…”

Investigation of the causal relationship between inflammatory bowel disease and type 2 diabetes mellitus: a Mendelian randomization study

“…According to a report, the global prevalence of diabetes among adults exceeded 460 million in 2019, with projections indicating a substantial increase to over 700 million by 2045 (Sun et al, 2022). Given its association with detrimental microvascular and macrovascular consequences, T2DM inflicts physical and psychological distress on patients and imposes a significant financial burden on the healthcare system (Kang et al, 2022;Alemayehu et al, 2023;Hands et al, 2023). Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, manifests in around 1% of the population and is commonly distinguished by persistent diarrhea (with or without bleeding), stomach discomfort, and loss of body mass (Bruner et al, 2023).…”